EXTI - only public co. developing liver device Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : EXTI - only public co. developing liver device

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Buendia who wrote (163)	1/27/1998 4:57:00 PM
From: LesX	Read Replies (3) of 1063

Spoke with Gerald Newmin today. Here are some highlights of the conversation: Gerald says he expects that the private placement will be complete in this quarter for around $1M. The overall funding needs are between $3-5M to bring the product to market. Initial funding requirements are between $200-300k for the first round of research at Loyola. Loyola research will commence prior to the Yale research. There are currently 10 prototype systems available. Three are in China (which they are trying to get back) 1 at Loyola, 1 at Yale and the remaining are in San Diego. The advantage to the Xenogenic machine is that it extends the life of the pig cells; hence, creating a cost savings on the order of 20:1 when compared to similar processes that have a problem keeping the cells alive. The FDA and NIH recently authorized using pig cells for this process requiring sufficient quality control from the cell sources. When asked of the possibility of a buyout he stated that is quite often the case as the technology matures. -That's all folks-

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next